CA3093128C - Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer - Google Patents

Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer Download PDF

Info

Publication number
CA3093128C
CA3093128C CA3093128A CA3093128A CA3093128C CA 3093128 C CA3093128 C CA 3093128C CA 3093128 A CA3093128 A CA 3093128A CA 3093128 A CA3093128 A CA 3093128A CA 3093128 C CA3093128 C CA 3093128C
Authority
CA
Canada
Prior art keywords
gene
genes
patient
recurrence
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3093128A
Other languages
English (en)
French (fr)
Other versions
CA3093128A1 (en
Inventor
Steven Shak
George Andrew Watson
Michael R. CRAGER
Tara Maddala
Margarita Lopatin
Audrey Goddard
Dejan Knezevic
Christer SVEDMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genomic Health Inc
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of CA3093128A1 publication Critical patent/CA3093128A1/en
Application granted granted Critical
Publication of CA3093128C publication Critical patent/CA3093128C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Databases & Information Systems (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Computing Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3093128A 2013-05-30 2014-05-29 Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer Active CA3093128C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361829100P 2013-05-30 2013-05-30
US61/829,100 2013-05-30
CA2903878A CA2903878C (en) 2013-05-30 2014-05-29 Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2903878A Division CA2903878C (en) 2013-05-30 2014-05-29 Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer

Publications (2)

Publication Number Publication Date
CA3093128A1 CA3093128A1 (en) 2014-12-04
CA3093128C true CA3093128C (en) 2023-01-03

Family

ID=51989393

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3093128A Active CA3093128C (en) 2013-05-30 2014-05-29 Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
CA2903878A Active CA2903878C (en) 2013-05-30 2014-05-29 Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2903878A Active CA2903878C (en) 2013-05-30 2014-05-29 Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer

Country Status (11)

Country Link
US (3) US10181008B2 (enExample)
EP (2) EP3004392B1 (enExample)
JP (3) JP2016521979A (enExample)
AU (2) AU2014274135B2 (enExample)
CA (2) CA3093128C (enExample)
DK (1) DK3004392T3 (enExample)
ES (1) ES2829415T3 (enExample)
IL (2) IL240919B (enExample)
MX (2) MX369911B (enExample)
SG (2) SG10201709537PA (enExample)
WO (1) WO2014194078A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187767A1 (en) * 2017-04-06 2018-10-11 The Regents Of The University Of California Predicting, diagnosing, and treating nausea and vomiting of pregnancy
WO2019075251A2 (en) * 2017-10-12 2019-04-18 Nantomics, Llc CANCER SCORE FOR EVALUATION AND PREDICTION OF RESPONSE FROM BIOLOGICAL FLUIDS
WO2020092808A1 (en) 2018-10-31 2020-05-07 Regents Of The University Of Minnesota Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer
KR102280204B1 (ko) * 2018-12-13 2021-07-21 연세대학교 산학협력단 신장 세포 암의 종양의 병리학적 등급에 대한 정보를 제공하기 위한 방법 및 장치
WO2020146745A1 (en) * 2019-01-11 2020-07-16 Quadrus Medical Technologies, Inc. Systems and methods for assessing and evaluating renal health diagnosis, staging, and therapy recommendation
EP3978629A1 (en) * 2020-10-01 2022-04-06 Koninklijke Philips N.V. Prediction of an outcome of a bladder or kidney cancer subject
CN113593640B (zh) * 2021-08-03 2023-07-28 哈尔滨市米杰生物科技有限公司 一种鳞癌组织功能状态与细胞组分评估方法及系统
WO2025085824A1 (en) * 2023-10-20 2025-04-24 Memorial Sloan-Kettering Cancer Center Multi-scale analysis of ribonucleic acid sequence data for predicting responses to anti-cancer therapies
CN117935910B (zh) * 2024-01-26 2024-09-17 华中农业大学 玉米snp位点的筛选方法、装置、电子设备及介质

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135314B1 (en) 1997-04-17 2006-11-14 Cell Therapeutics, Inc. Human phosphatidic acid phosphatase
CN1425066B (zh) 2000-01-13 2010-05-26 杰南技术公司 新的stra6多肽
US6475855B1 (en) 2000-03-01 2002-11-05 Micron Technology, Inc. Method of forming integrated circuitry, method of forming a capacitor and method of forming DRAM integrated circuitry
DE10126344A1 (de) 2000-07-14 2002-01-24 Max Planck Gesellschaft Apoptose-induzierende DNA-Sequenzen
AU2001294842A1 (en) 2000-09-28 2002-04-08 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
US20030109434A1 (en) 2001-03-19 2003-06-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
US20060088823A1 (en) 2001-03-29 2006-04-27 Brian Haab Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification
PT1410011E (pt) 2001-06-18 2011-07-25 Rosetta Inpharmatics Llc Diagnóstico e prognóstico de pacientes com cancro da mama
US7470509B2 (en) 2002-02-08 2008-12-30 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
US7081340B2 (en) 2002-03-13 2006-07-25 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
JP2006501849A (ja) 2002-10-04 2006-01-19 ヴァン アンデル リサーチ インスティチュート 腎腫瘍の分子サブ分類および新規診断マーカーの発見
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
AU2004235395A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
CA3061769C (en) 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
JP2007526749A (ja) 2003-07-02 2007-09-20 ノバルティス アクチエンゲゼルシャフト 予後および治療標的として卵巣癌で調節される遺伝子
US20050002904A1 (en) 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
ES2905579T3 (es) * 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
JP2005211023A (ja) 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
US20070224596A1 (en) 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
CA2563074C (en) * 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
AU2005241093B2 (en) * 2004-05-04 2008-06-05 Institute Of Virology Of Slovak Academy Of Sciences MN/CA IX/ CA9 and renal cancer prognosis
CA2568405A1 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Biomarkers for monitoring inhibition of impdh pathway
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US20080119367A1 (en) 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
WO2006083986A2 (en) 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of Health & Human Services Biomarkers for tissue status
KR20070115891A (ko) 2005-02-18 2007-12-06 와이어쓰 충실성 종양의 예후전망을 위한 약물유전학 마커
EP1910564A1 (en) 2005-05-13 2008-04-16 Duke University Gene expression signatures for oncogenic pathway deregulation
WO2006124022A1 (en) 2005-05-13 2006-11-23 Vanandel Research Institute Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma
US20070037186A1 (en) 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
EP2687608B1 (en) 2005-06-08 2017-02-08 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1893581B1 (en) 2005-06-15 2010-01-27 Pfizer Limited Substituted arylpyrazoles for use against parasitites
EP2154245B1 (en) 2005-09-02 2015-11-11 Toray Industries, Inc. Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient
CA2621932A1 (en) 2005-09-14 2007-03-22 Human Genetic Signatures Pty Ltd Assay for hpv and methylated genomic dna targets to screen for cervical cancer
AU2006299079A1 (en) 2005-09-30 2007-04-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
WO2007072225A2 (en) 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20070141066A1 (en) 2005-12-16 2007-06-21 Genentech, Inc. Method for Diagnosing, Prognosing and Treating Glioma
WO2007146668A2 (en) 2006-06-06 2007-12-21 University Of Massachusetts Use of imp3 as a prognostic marker for cancer
WO2008021183A2 (en) 2006-08-10 2008-02-21 Millennium Pharmaceuticals, Inc. For the identification, assessment, and treatment of patients with cancer therapy
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
WO2008083098A1 (en) * 2006-12-27 2008-07-10 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
US20080286273A1 (en) 2007-05-02 2008-11-20 Siemens Medical Solutions Usa, Inc. Knowledge-Based Proliferation Signatures and Methods of Use
EP1990417A1 (en) 2007-05-11 2008-11-12 Universität Bayreuth Archaeal plasmid vector system
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
EP3831954A3 (en) 2008-11-17 2021-10-13 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
US20120142553A1 (en) 2009-06-26 2012-06-07 Franciscus Petrus Smit Molecular Markers in Kidney Cancer
US9005891B2 (en) 2009-11-10 2015-04-14 Genomic Health, Inc. Methods for depleting RNA from nucleic acid samples
EP4350001A3 (en) * 2009-11-23 2024-06-19 Genomic Health, Inc. Methods to predict clinical outcome of cancer
US9551034B2 (en) 2010-01-11 2017-01-24 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
EP2721179A4 (en) * 2011-06-16 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L BIOMARKER COMPOSITIONS AND METHOD THEREFOR
WO2013028807A2 (en) 2011-08-22 2013-02-28 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof

Also Published As

Publication number Publication date
EP3004392A1 (en) 2016-04-13
US11551782B2 (en) 2023-01-10
MX369911B (es) 2019-11-26
US20220044760A9 (en) 2022-02-10
US10181008B2 (en) 2019-01-15
MX2019013953A (es) 2020-01-30
ES2829415T3 (es) 2021-05-31
AU2020204502A1 (en) 2020-07-23
CA3093128A1 (en) 2014-12-04
MX2015012782A (es) 2016-02-05
AU2020204502B2 (en) 2022-02-17
WO2014194078A1 (en) 2014-12-04
US20190095575A1 (en) 2019-03-28
SG10201709537PA (en) 2017-12-28
IL283548A (en) 2021-07-29
JP7301798B2 (ja) 2023-07-03
EP3004392B1 (en) 2020-09-30
SG11201506987VA (en) 2015-10-29
JP2020191896A (ja) 2020-12-03
JP2018161151A (ja) 2018-10-18
US20210151122A1 (en) 2021-05-20
HK1223132A1 (en) 2017-07-21
JP2016521979A (ja) 2016-07-28
AU2014274135B2 (en) 2020-04-09
CA2903878A1 (en) 2014-12-04
EP3825420A1 (en) 2021-05-26
IL240919B (en) 2021-06-30
IL240919A0 (en) 2015-10-29
NZ752676A (en) 2021-05-28
US20160048632A1 (en) 2016-02-18
DK3004392T3 (da) 2020-10-26
NZ711680A (en) 2021-05-28
AU2014274135A1 (en) 2015-09-24
EP3004392A4 (en) 2017-01-25
CA2903878C (en) 2020-10-27

Similar Documents

Publication Publication Date Title
JP7042784B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP7385630B2 (ja) 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法
US11551782B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
AU2010321829A1 (en) Methods to predict clinical outcome of cancer
EP3580357A1 (en) Algorithms and methods for assessing late clinical endpoints in prostate cancer
AU2017268510A1 (en) Method for using gene expression to determine prognosis of prostate cancer
US20110287958A1 (en) Method for Using Gene Expression to Determine Colorectal Tumor Stage
HK40052881A (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
HK1223132B (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
AU2015202116B2 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ752676B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
NZ711680B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200915

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250523

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250523